Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136435 · ClinicalTrials.gov registry record · Phase 2
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00136435 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants.
The verdict
NCT00136435, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
Interventions
- DRUG prednisone
- DRUG doxorubicin
- DRUG vincristine
- DRUG methotrexate
- DRUG asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136435
The ClinicalTrials.gov registry entry for NCT00136435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00136435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136435 about?
NCT00136435 is a clinical study titled "A Study in Adults With Untreated Acute Lymphoblastic Leukemia". The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
What is the current status of trial NCT00136435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2002-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00136435?
The interventions under investigation include: prednisone (DRUG), doxorubicin (DRUG), vincristine (DRUG), methotrexate (DRUG), asparaginase (DRUG).
Who is sponsoring clinical trial NCT00136435?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.